Abstract P066 – Table 1. Baseline characteristics of experienced patients in study.
Variables at enrolment	Doravirine n = 128 mean SD or n (%) or median (IQR)	Rilpivirine n = 331 mean SD or n (%) or median (IQR)	p
Age, years	53.6±12.4	42.3±9.3	<0.0001
Sex, M	91 (71.1%)	237 (71.6%)	0.91
BMI, kg/m2	26.2±5.5	24.4±3.8	0.0002
Weight, kg	77.3±17.6	81.7±14.3	0.0007
Caucasian	117 (91.4%)	304 (91.8%)	0.88
Risk factor for HIV acquisition: sexual	89 (69.5%)	244 (73.7%)	0.16
Risk factor for HIV acquisition: IDU	24 (18.8%)	66 (19.9%)	0.16
Risk factor for HIV acquisition: other/ND	15 (11.7%)	21 (6.3%)	0.16
HBV coinfection (n = 102/321)	8 (7.8%)	20 (6.2%)	0.57
HCV coinfection (n = 107/329)	26 (24.3%)	76 (23.1%)	0.80
Detectable HIV‐RNA	16 (12.5%)	50 (15.1%)	0.48
Previous ART: PI	29 (22.7%)	152 (45.9%)	<0.0001
Previous ART: INSTI	62 (48.4%)	17 (5.1%)	<0.0001
Previous ART: NNRTI	47 (36.7%)	151 (45.6%)	0.08
CD4, cells/mm3	685 (493 to 955)	624 (443 to 820)	0.02
Total cholesterol, mg/dL	198±45	189±42	0.06
HDL‐cholesterol, mg/dL	51±15	48±16	0.08
LDL‐cholesterol, mg/dL	118±38	112±38	0.12
Triglycerides, mg/dL	114 (85 to 153)	120 (85 to 172)	0.56
On lipid‐lowering drugs	25 (19.5%)	29 (8.8%)	0.001
AST, UI/dL	21 (18 to 29)	24 (19 to 31)	0.008
ALT, UI/dL	24 (17 to 32)	28 (21 to 42)	0.0007